Compare Paychex, Inc. (PAYX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs TG Therapeutics Inc — how do they compare? Paychex, Inc. trades at $104.06 (market cap $37.19B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Paychex, Inc. is far larger — about 4.6× TG Therapeutics Inc's market cap, and Paychex, Inc. pays a 4.56% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Paychex, Inc. for 56 Days and TG Therapeutics Inc for 16 Days on average.
| PAYX | TGTX | |
|---|---|---|
Market Cap | $37.19B | $8.16B |
Volume | 3,344,316 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $128.59 | $59.06 |
52-Week Low | $85.57 | $26.94 |
Typical Hold Time | 56 Days | 16 Days |
Enterprise Value | $40.87B | $8.37B |
Dividend Yield | 4.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $103.98, up 2.39% with a bullish technical signal despite mixed indicators. The company demonstrates strong fundamentals with consistent earnings beats, 27.35% net margins, and robust profitability metrics. Recent news highlights investor concerns about dividend sustainability despite solid Q1 2027 results showing 6% revenue growth and double-digit earnings increases driven by PEO and insurance segments.
Outlook remains cautiously optimistic with a $111 consensus price target offering 6.8% upside. Key risks include labor market sensitivity and competitive pressures, while opportunities lie in AI integration and PEO growth. The stock presents a balanced risk-reward profile with dividend stability supporting investor returns.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
